Jammu Journal

Pneumococcal Pneumonia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

 Breaking News
  • No posts were found

Pneumococcal Pneumonia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

June 21
19:30 2024
Pneumococcal Pneumonia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Pneumonia, Pneumococcal Pipeline Insight 2024” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in the Pneumonia, Pneumococcal pipeline landscape. It covers the Pneumococcal Pneumonia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pneumococcal Pneumonia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Pneumococcal Pneumonia Research. Learn more about our innovative pipeline today! @ Pneumococcal Pneumonia Pipeline Outlook

 

Key Takeaways from the Pneumococcal Pneumonia Pipeline Report

  • June 20, 2024- Merck’s newly approved pneumococcal vaccine is expected to compete with Pfizer’s existing vaccines, pending CDC recommendations later this month. On June 17, 2024, the United States FDA approved CAPVAXIVE, a pneumococcal 21-valent conjugate vaccine that actively prevents invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B.

  • May 2024:- GlaxoSmithKline– This is a Phase 2 clinical study to support the use of AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of 3 different dose levels of AFX3772 compared with PCV13.

  • March 2024:- Vaxcyte Inc.- Randomized, Observer-Blind, Active-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of 24-Valent PCV (VAX-24) in Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age With Pediatric Vaccines. The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.
  • DelveInsight’s Pneumococcal Pneumonia pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies for Pneumococcal Pneumonia treatment.
  • The leading Pneumococcal Pneumonia Companies such as Vaxcyte, Merck & Co, Affinivax, GlaxoSmithKline, Pfizer, EuBiologics, and others.
  • Promising Pneumococcal Pneumonia Therapies such as PPV23, PCV13, AFX3772, Prevnar 13, COVID-19 vaccine, IIV4+PPV23, and others.

 

Stay informed about the cutting-edge advancements in Pneumococcal Pneumonia Treatments. Download for updates and be a part of the revolution in cancer care @ Pneumococcal Pneumonia Clinical Trials Assessment 

 

Pneumococcal Pneumonia Emerging Drugs Profile

  • V116: Merck & Co

V116, the company’s investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. V116 is designed to specifically target serotypes that are responsible for 85 percent of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 20191. Importantly, the eight serotypes in V116 that are not included in any currently-licensed pneumococcal vaccine account for over 30 percent of this disease burden alone.

 

Learn more about Pneumococcal Pneumonia Drugs opportunities in our groundbreaking Pneumococcal Pneumonia Research and development projects @ Pneumococcal Pneumonia Unmet Needs

 

Pneumonia, Pneumococcal pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intranasal
  • Intrathecal
  • Intravenous
  • Oral
  • Oral/Intravenous
  • Parenteral
  • Subcutaneous
  • Subcutaneous/Intramuscular
  • Transdermal

 

Pneumococcal Pneumonia Products have been categorized under various Molecule types such as

  • Antisense oligonucleotide
  • Gene therapy
  • Hormones
  • Neuropeptides
  • Oligonucleotides
  • Small Molecule
  • Triglyceride

 

Discover the latest advancements in Pneumococcal Pneumonia Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Pneumococcal Pneumonia Market Drivers and Barriers, and Future Perspectives

 

Scope of the Pneumococcal Pneumonia Pipeline Report

  • Coverage- Global
  • Pneumococcal Pneumonia Companies- Vaxcyte, Merck & Co, Affinivax, GlaxoSmithKline, Pfizer, EuBiologics, and others.
  • Pneumococcal Pneumonia Therapies- PPV23, PCV13, AFX3772, Prevnar 13, COVID-19 vaccine, IIV4+PPV23, and others.
  • Pneumococcal Pneumonia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pneumococcal Pneumonia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Pneumococcal Pneumonia Pipeline on our website @ Pneumococcal Pneumonia Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pneumonia, Pneumococcal: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pneumonia, Pneumococcal– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. V116: Merck & Co
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. VAX-24: Vaxcyte
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. Drug profiles in the detailed report…..
  18. Preclinical Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Pneumonia, Pneumococcal Key Companies
  23. Pneumonia, Pneumococcal Key Products
  24. Pneumonia, Pneumococcal- Unmet Needs
  25. Pneumonia, Pneumococcal- Market Drivers and Barriers
  26. Pneumonia, Pneumococcal- Future Perspectives and Conclusion
  27. Pneumonia, Pneumococcal Analyst Views
  28. Pneumonia, Pneumococcal Key Companies
  29. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/